Protalix BioTherapeutics
PLX
#7457
Rank
$92.04 M
Marketcap
$1.26
Share price
0.80%
Change (1 day)
-39.13%
Change (1 year)

P/E ratio for Protalix BioTherapeutics (PLX)

P/E ratio as of March 2024 (TTM): 12.6

According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.6. At the end of 2022 the company had a P/E ratio of -4.57.

P/E ratio history for Protalix BioTherapeutics from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-4.57241.12%
2021-1.34-94.84%
2020-25.9880.23%
2019-2.6562.12%
2018-1.6361.54%
2017-1.01-93.49%
2016-15.5-194.32%
201516.5-129.51%
2014-55.8-57%
2013-130-67.52%
2012-399142.94%
2011-164-7.79%
2010-17810.37%
2009-161172.03%
2008-59.4720.49%
2007-7.23-98.54%
2006-4971052.86%
2005-43.11680.87%
2004-2.42-96.97%
2003-80.0263.64%
2002-22.0-4.35%
2001-23.0

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
14.9 18.41%๐Ÿ‡บ๐Ÿ‡ธ USA
70.4 458.47%๐Ÿ‡บ๐Ÿ‡ธ USA
-18.4-246.08%๐Ÿ‡บ๐Ÿ‡ธ USA
-7.06-155.99%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.